| In Vivo PICX CAR-T Therapy for R/R Multiple Myeloma (NCT07715630) | Chongqing Precision Biotech Co., Ltd | 2026-07-31 |
| Non-Interventional Study of Puzol-cel for CD19-Positive Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (NCT07637929) | Chongqing Precision Biotech Co., Ltd | 2026-06-01 |
| PIC1 Injection Therapy for Relapsed/Refractory B-NHL (NCT07456371) | Chongqing Precision Biotech Co., Ltd | 2026-03-01 |
| Study of CD19 CAR-T Therapy for Refractory SLE (NCT07403097) | Chongqing Precision Biotech Co., Ltd | 2026-02-01 |
| Study of Ultra-Fast BCMA/CD70 CAR-T Therapy for Refractory SLE (NCT07318259) | Chongqing Precision Biotech Co., Ltd | 2026-01-26 |
| Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE (NCT07331467) | Chongqing Precision Biotech Co., Ltd | 2026-01-01 |
| CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors (NCT07181720) | Chongqing Precision Biotech Co., Ltd | 2025-09-12 |
| CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors (NCT07179692) | Chongqing Precision Biotech Co., Ltd | 2025-09-12 |
| Clinical Study of BCMA/CD70-targeted CAR-T Therapy for Refractory Pediatric Rheumatic Diseases (NCT07184450) | Chongqing Precision Biotech Co., Ltd | 2025-09-01 |
| In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies (NCT07239323) | Chongqing Precision Biotech Co., Ltd | 2025-07-01 |
| Clinical Trial of CD19 Targeted CAR-T Cell in Refractory Adult SLE (NCT06892145) | Chongqing Precision Biotech Co., Ltd | 2025-06-12 |
| Targeted Anti-CEA CAR-T Immunotherapy for Advanced Lung Cancer (NCT06992583) | Chongqing Precision Biotech Co., Ltd | 2025-05-08 |
| Clinical Study on Chimeric Antigen Receptor T Lymphocyte (CAR-T) Targeting CEA for the Treatment of CEA - Positive Advanced Lung Cancer (NCT06945523) | Chongqing Precision Biotech Co., Ltd | 2025-04-28 |
| Clinical Trial of CD5-targeted CAR-NK Therapy for Relapse/Refractory T-Cell Hematologic Malignancies (NCT06909474) | Chongqing Precision Biotech Co., Ltd | 2025-03-27 |
| Anti-CEA CAR-T for Advanced CEA-Positive Lung Carcinoma (NCT06903117) | Chongqing Precision Biotech Co., Ltd | 2025-03-24 |
| A Clinical Trial of CEA Targeting CAR-T for CEA Positive Advanced Lung Cancer (NCT06768151) | Chongqing Precision Biotech Co., Ltd | 2024-12-12 |
| Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/refractory AML or BPDCN (NCT06690827) | Chongqing Precision Biotech Co., Ltd | 2024-11-13 |
| Clinical Study of CD19 Targeted Universal Chimeric Antigen Receptor T Lymphocytes (UCAR-T) for the Treatment of Refractory Juvenile Dermatomyositis (RJDM) (NCT06686524) | Chongqing Precision Biotech Co., Ltd | 2024-11-11 |
| Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/ Refractory B-ALL (NCT06641024) | Chongqing Precision Biotech Co., Ltd | 2024-11-01 |
| Clinical Trial of CD19-targeted CAR-T Therapy for Refractory Juvenile Dermatomyositis (NCT06569472) | Chongqing Precision Biotech Co., Ltd | 2024-07-02 |
| Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm (NCT06006403) | Chongqing Precision Biotech Co., Ltd | 2024-03-28 |
| A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Gynecologic Cancer (NCT06215950) | Chongqing Precision Biotech Co., Ltd | 2024-01-10 |
| Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/Refractory B Cell Lymphoma (NCT06180174) | Chongqing Precision Biotech Co., Ltd | 2023-12-31 |
| A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors (NCT06010875) | Chongqing Precision Biotech Co., Ltd | 2023-11-30 |
| Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes（CAR-T） for CEA Positive Advanced Malignant Solid Tumors (NCT06126406) | Chongqing Precision Biotech Co., Ltd | 2023-11-06 |
| Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors (NCT06010862) | Chongqing Precision Biotech Co., Ltd | 2023-09-30 |
| CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors (NCT06006390) | Chongqing Precision Biotech Co., Ltd | 2023-09-07 |
| A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors (NCT06043466) | Chongqing Precision Biotech Co., Ltd | 2023-08-11 |
| A Clinical Research About CD70-positive Advanced/Metastatic Solid Tumors Treated by CD70-targeted CAR-T (NCT05468190) | Chongqing Precision Biotech Co., Ltd | 2022-07-17 |
| Safety and Efficacy of CEA-targeted CAR-T for CEA-positive Advanced Malignant Solid Tumors (NCT05538195) | Chongqing Precision Biotech Co., Ltd | 2022-06-07 |
| A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents (NCT05334823) | Chongqing Precision Biotech Co., Ltd | 2022-01-26 |
| Clinical Study of CD70-targeted CAR-T Therapy for Advanced/Advanced Renal Cancer (NCT05420519) | Chongqing Precision Biotech Co., Ltd | 2021-12-31 |
| A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors (NCT05420545) | Chongqing Precision Biotech Co., Ltd | 2021-12-31 |
| Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors (NCT05415475) | Chongqing Precision Biotech Co., Ltd | 2021-09-10 |
| Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma (NCT05420493) | Chongqing Precision Biotech Co., Ltd | 2021-09-06 |
| Dual-target CAR-T Cells (C-4-29) in the Treatment of Relapsed/Refractory Multiple Myeloma (NCT04861480) | Chongqing Precision Biotech Co., Ltd | 2021-06-16 |
| a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B Cell Lymphoma (NCT04782193) | Chongqing Precision Biotech Co., Ltd | 2021-05-23 |
| a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B-ALL (NCT04781634) | Chongqing Precision Biotech Co., Ltd | 2021-03-07 |
| a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease (NCT04776330) | Chongqing Precision Biotech Co., Ltd | 2021-03-07 |
| Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma (NCT04648475) | Chongqing Precision Biotech Co., Ltd | 2020-08-25 |
| Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer (NCT04348643) | Chongqing Precision Biotech Co., Ltd | 2020-02-20 |
| Safety and Efficacy of CD123-Targeted CAR-T Therapy for Relapsed/Refractory Acute Myeloid Leukemia (NCT04272125) | Chongqing Precision Biotech Co., Ltd | 2019-12-01 |
| Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma (NCT04272151) | Chongqing Precision Biotech Co., Ltd | 2019-12-01 |
| Phase I Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents (NCT04888468) | Chongqing Precision Biotech Co., Ltd | 2019-11-05 |
| CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma (NCT04649983) | Chongqing Precision Biotech Co., Ltd | 2019-09-01 |
| CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia (NCT04265963) | Chongqing Precision Biotech Co., Ltd | 2019-09-01 |
| CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma (NCT04271410) | Chongqing Precision Biotech Co., Ltd | 2019-06-01 |
| BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease (NCT04271644) | Chongqing Precision Biotech Co., Ltd | 2019-04-01 |